235 related articles for article (PubMed ID: 16441227)
41. Rational Design of Allosteric and Selective Inhibitors of the Molecular Chaperone TRAP1.
Sanchez-Martin C; Moroni E; Ferraro M; Laquatra C; Cannino G; Masgras I; Negro A; Quadrelli P; Rasola A; Colombo G
Cell Rep; 2020 Apr; 31(3):107531. PubMed ID: 32320652
[TBL] [Abstract][Full Text] [Related]
42. Detecting the Potential Pharmacological Synergy of Drug Combination by Viability Assays In Vitro.
Gibbs BK; Sourbier C
Methods Mol Biol; 2018; 1709():129-137. PubMed ID: 29177656
[TBL] [Abstract][Full Text] [Related]
43. Steroid receptor interactions with heat shock protein and immunophilin chaperones.
Pratt WB; Toft DO
Endocr Rev; 1997 Jun; 18(3):306-60. PubMed ID: 9183567
[TBL] [Abstract][Full Text] [Related]
44. [Thermosensitization of tumor cells with inhibitors of chaperone activity and expression].
Kudriavtsev VA; Makarova IuM; Kabakav AE
Biomed Khim; 2012; 58(6):662-72. PubMed ID: 23350198
[TBL] [Abstract][Full Text] [Related]
45. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol.
Sharma SV; Agatsuma T; Nakano H
Oncogene; 1998 May; 16(20):2639-45. PubMed ID: 9632140
[TBL] [Abstract][Full Text] [Related]
46. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
47. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
48. The epichaperome is an integrated chaperome network that facilitates tumour survival.
Rodina A; Wang T; Yan P; Gomes ED; Dunphy MP; Pillarsetty N; Koren J; Gerecitano JF; Taldone T; Zong H; Caldas-Lopes E; Alpaugh M; Corben A; Riolo M; Beattie B; Pressl C; Peter RI; Xu C; Trondl R; Patel HJ; Shimizu F; Bolaender A; Yang C; Panchal P; Farooq MF; Kishinevsky S; Modi S; Lin O; Chu F; Patil S; Erdjument-Bromage H; Zanzonico P; Hudis C; Studer L; Roboz GJ; Cesarman E; Cerchietti L; Levine R; Melnick A; Larson SM; Lewis JS; Guzman ML; Chiosis G
Nature; 2016 Oct; 538(7625):397-401. PubMed ID: 27706135
[TBL] [Abstract][Full Text] [Related]
49. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
Özgür A; Tutar Y
Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
[TBL] [Abstract][Full Text] [Related]
50. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
51. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F; Kihara K; Neckers L
Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
[TBL] [Abstract][Full Text] [Related]
53. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
[TBL] [Abstract][Full Text] [Related]
54. Evidence for chaperone heterocomplexes containing both Hsp90 and VCP.
Prince T; Shao J; Matts RL; Hartson SD
Biochem Biophys Res Commun; 2005 Jun; 331(4):1331-7. PubMed ID: 15883021
[TBL] [Abstract][Full Text] [Related]
55. Emerging Roles of Extracellular Hsp90 in Cancer.
Wong DS; Jay DG
Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
[TBL] [Abstract][Full Text] [Related]
56. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression.
Akalin A; Elmore LW; Forsythe HL; Amaker BA; McCollum ED; Nelson PS; Ware JL; Holt SE
Cancer Res; 2001 Jun; 61(12):4791-6. PubMed ID: 11406554
[TBL] [Abstract][Full Text] [Related]
57. Discovery and development of purine-scaffold Hsp90 inhibitors.
Chiosis G
Curr Top Med Chem; 2006; 6(11):1183-91. PubMed ID: 16842155
[TBL] [Abstract][Full Text] [Related]
58. Functional specificity of co-chaperone interactions with Hsp90 client proteins.
Riggs DL; Cox MB; Cheung-Flynn J; Prapapanich V; Carrigan PE; Smith DF
Crit Rev Biochem Mol Biol; 2004; 39(5-6):279-95. PubMed ID: 15763706
[TBL] [Abstract][Full Text] [Related]
59. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
60. Hsp90: a chaperone for protein folding and gene regulation.
Zhao R; Houry WA
Biochem Cell Biol; 2005 Dec; 83(6):703-10. PubMed ID: 16333321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
